Cover Page
Cover Page - shares | 9 Months Ended | |
Sep. 30, 2023 | May 13, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-39011 | |
Entity Registrant Name | EXICURE, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 81-5333008 | |
Entity Address, Address Line One | 2430 N. Halsted St. | |
Entity Address, City or Town | Chicago | |
Entity Address, State or Province | IL | |
Entity Address, Postal Zip Code | 60614 | |
City Area Code | (847) | |
Local Phone Number | 673-1700 | |
Title of 12(b) Security | Common Stock, par value $0.0001 per share | |
Trading Symbol | XCUR | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding (in shares) | 8,651,006 | |
Entity Central Index Key | 0001698530 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
UNAUDITED CONDENSED CONSOLIDATE
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 922 | $ 8,577 |
Other receivable, from sale of property and equipment | 711 | 0 |
Prepaid expenses and other assets | 1,457 | 1,474 |
Total current assets | 3,090 | 10,051 |
Property and equipment, net | 61 | 2,530 |
Right-of-use asset | 6,707 | 7,257 |
Other noncurrent assets | 3,092 | 3,490 |
Total assets | 12,950 | 23,328 |
Current liabilities: | ||
Accounts payable | 865 | 361 |
Accrued expenses and other current liabilities | 1,356 | 1,278 |
Total current liabilities | 2,221 | 1,639 |
Lease liability, noncurrent | 6,231 | 6,767 |
Total liabilities | 8,452 | 8,406 |
Commitments and Contingencies (Note 11) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, September 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 8,650,515 issued and outstanding, September 30, 2023; 4,965,901 issued and outstanding, December 31, 2022 | 1 | 0 |
Additional paid-in capital | 192,573 | 187,571 |
Accumulated deficit | (188,076) | (172,649) |
Total stockholders’ equity | 4,498 | 14,922 |
Total liabilities and stockholders’ equity | $ 12,950 | $ 23,328 |
UNAUDITED CONDENSED CONSOLIDA_2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Sep. 30, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 8,650,515 | 4,965,901 |
Common stock, shares outstanding (in shares) | 8,650,515 | 4,965,901 |
UNAUDITED CONDENSED CONSOLIDA_3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Revenue: | ||||
Collaboration revenue | $ 0 | $ 2,016,000 | $ 0 | $ 7,052,000 |
Total revenue | 0 | 2,016,000 | 0 | 7,052,000 |
Operating expenses: | ||||
Research and development expense | 0 | 4,805,000 | 1,423,000 | 18,694,000 |
General and administrative expense | 2,397,000 | 2,416,000 | 11,155,000 | 8,783,000 |
Loss from sale of property and equipment | 920,000 | 0 | 920,000 | 0 |
Total operating expenses | 3,317,000 | 7,221,000 | 13,498,000 | 27,477,000 |
Operating loss | (3,317,000) | (5,205,000) | (13,498,000) | (20,425,000) |
Other income (expense), net: | ||||
Change in fair value of investment in convertible notes receivable | (2,000,000) | 0 | (2,000,000) | 0 |
Dividend income | 13,000 | 41,000 | 45,000 | 59,000 |
Interest income | 4,000 | 4,000 | 28,000 | 7,000 |
Interest expense | 0 | 0 | 0 | (595,000) |
Other income (expense), net | 44,000 | 0 | (2,000) | (24,000) |
Total other income (expense), net | (1,939,000) | 45,000 | (1,929,000) | (553,000) |
Net loss before provision for income taxes | (5,256,000) | (5,160,000) | (15,427,000) | (20,978,000) |
Provision for income taxes | 0 | 0 | 0 | 0 |
Net loss | $ (5,256,000) | $ (5,160,000) | $ (15,427,000) | $ (20,978,000) |
Basic loss per common share (in dollars per share) | $ (0.61) | $ (1.04) | $ (1.98) | $ (4.66) |
Diluted loss per common share (in dollars per share) | $ (0.61) | $ (1.04) | $ (1.98) | $ (4.66) |
Weighted-average basic common shares outstanding (in shares) | 8,650,402 | 4,963,344 | 7,799,233 | 4,502,962 |
Weighted-average diluted common shares outstanding (in shares) | 8,650,402 | 4,963,344 | 7,799,233 | 4,502,962 |
UNAUDITED CONDENSED CONSOLIDA_4
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Statement of Comprehensive Income [Abstract] | ||||
Net loss | $ (5,256) | $ (5,160) | $ (15,427) | $ (20,978) |
Other comprehensive gain, net of taxes | ||||
Unrealized gain on available for sale securities, net of tax | 0 | 4 | 0 | 1 |
Other comprehensive gain | 0 | 4 | 0 | 1 |
Comprehensive loss | $ (5,256) | $ (5,156) | $ (15,427) | $ (20,977) |
UNAUDITED CONDENSED CONSOLIDA_5
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in- Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) |
Beginning balance (in shares) at Dec. 31, 2021 | 3,626,073 | ||||
Beginning balance at Dec. 31, 2021 | $ 11,232 | $ 0 | $ 181,301 | $ (170,067) | $ (2) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Exercise of common stock warrants (in shares) | 466,666 | ||||
Exercise of common stock warrants | 14 | 14 | |||
Equity-based compensation | 342 | 342 | |||
Vesting of restricted stock units and related repurchases (in shares) | 324 | ||||
Vesting of restricted stock units and related repurchases | (1) | (1) | |||
Other comprehensive loss, net | (3) | (3) | |||
Net loss | (8,348) | (8,348) | |||
Ending balance (in shares) at Mar. 31, 2022 | 4,093,063 | ||||
Ending balance at Mar. 31, 2022 | 3,236 | $ 0 | 181,656 | (178,415) | (5) |
Beginning balance (in shares) at Dec. 31, 2021 | 3,626,073 | ||||
Beginning balance at Dec. 31, 2021 | 11,232 | $ 0 | 181,301 | (170,067) | (2) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Other comprehensive loss, net | 1 | ||||
Net loss | (20,978) | ||||
Ending balance (in shares) at Sep. 30, 2022 | 4,964,313 | ||||
Ending balance at Sep. 30, 2022 | (3,703) | $ 0 | 187,343 | (191,045) | (1) |
Beginning balance (in shares) at Mar. 31, 2022 | 4,093,063 | ||||
Beginning balance at Mar. 31, 2022 | 3,236 | $ 0 | 181,656 | (178,415) | (5) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Exercise of options (in shares) | 124 | ||||
Exercise of options | 1 | 1 | |||
Equity-based compensation | 507 | 507 | |||
Vesting of restricted stock units and related repurchases (in shares) | 324 | ||||
Vesting of restricted stock units and related repurchases | (1) | (1) | |||
Issuance of common stock-ESPP (in shares) | 1,351 | ||||
Issuance of common stock-ESPP | 4 | 4 | |||
Issuance of common stock and warrants (in shares) | 867,369 | ||||
Issuance of common stock and warrants | 4,886 | 4,886 | |||
Net loss | (7,470) | (7,470) | |||
Ending balance (in shares) at Jun. 30, 2022 | 4,962,231 | ||||
Ending balance at Jun. 30, 2022 | 1,163 | $ 0 | 187,053 | (185,885) | (5) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Equity-based compensation | 292 | 292 | |||
Vesting of restricted stock units and related repurchases (in shares) | 2,082 | ||||
Vesting of restricted stock units and related repurchases | (2) | (2) | |||
Other comprehensive loss, net | 4 | 4 | |||
Net loss | (5,160) | (5,160) | |||
Ending balance (in shares) at Sep. 30, 2022 | 4,964,313 | ||||
Ending balance at Sep. 30, 2022 | $ (3,703) | $ 0 | 187,343 | (191,045) | $ (1) |
Beginning balance (in shares) at Dec. 31, 2022 | 4,965,901 | 4,965,901 | |||
Beginning balance at Dec. 31, 2022 | $ 14,922 | $ 0 | 187,571 | (172,649) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Equity-based compensation | 308 | 308 | |||
Reclassification of common stock warrants to liability | (800) | (800) | |||
Vesting of restricted stock units and related repurchases (in shares) | 5,561 | ||||
Vesting of restricted stock units and related repurchases | (1) | $ 1 | (2) | ||
Issuance of common stock and warrants (in shares) | 3,400,000 | ||||
Issuance of common stock and warrants | 4,597 | 4,597 | |||
Net loss | (4,407) | (4,407) | |||
Ending balance (in shares) at Mar. 31, 2023 | 8,371,462 | ||||
Ending balance at Mar. 31, 2023 | $ 14,619 | $ 1 | 191,674 | (177,056) | |
Beginning balance (in shares) at Dec. 31, 2022 | 4,965,901 | 4,965,901 | |||
Beginning balance at Dec. 31, 2022 | $ 14,922 | $ 0 | 187,571 | (172,649) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Exercise of options (in shares) | 0 | ||||
Other comprehensive loss, net | $ 0 | ||||
Net loss | $ (15,427) | ||||
Ending balance (in shares) at Sep. 30, 2023 | 8,650,515 | 8,650,515 | |||
Ending balance at Sep. 30, 2023 | $ 4,498 | $ 1 | 192,573 | (188,076) | |
Beginning balance (in shares) at Mar. 31, 2023 | 8,371,462 | ||||
Beginning balance at Mar. 31, 2023 | 14,619 | $ 1 | 191,674 | (177,056) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Equity-based compensation | 969 | 969 | |||
Vesting of restricted stock units and related repurchases (in shares) | 276,845 | ||||
Vesting of restricted stock units and related repurchases | (119) | (119) | |||
Net loss | (5,764) | (5,764) | |||
Ending balance (in shares) at Jun. 30, 2023 | 8,648,307 | ||||
Ending balance at Jun. 30, 2023 | 9,705 | $ 1 | 192,524 | (182,820) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Equity-based compensation | 50 | 50 | |||
Vesting of restricted stock units and related repurchases (in shares) | 2,208 | ||||
Vesting of restricted stock units and related repurchases | (1) | (1) | |||
Other comprehensive loss, net | 0 | ||||
Net loss | $ (5,256) | (5,256) | |||
Ending balance (in shares) at Sep. 30, 2023 | 8,650,515 | 8,650,515 | |||
Ending balance at Sep. 30, 2023 | $ 4,498 | $ 1 | $ 192,573 | $ (188,076) |
UNAUDITED CONDENSED CONSOLIDA_6
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Cash flows from operating activities: | ||
Net loss | $ (15,427) | $ (20,978) |
Adjustments to reconcile net loss to cash used in operating activities: | ||
Depreciation and amortization | 627 | 882 |
Equity-based compensation | 1,327 | 1,141 |
Amortization of long-term debt issuance costs and fees | 0 | 477 |
Amortization of right-of-use asset | 551 | 516 |
Amortization of investments | 0 | (2) |
Changes in fair value of investment in convertible notes receivable | 2,000 | 0 |
Loss from sale of property and equipment | 920 | 23 |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | 124 | 2,973 |
Other noncurrent assets | 291 | 48 |
Accounts payable | 504 | (2,493) |
Accrued expenses | 78 | (3,448) |
Deferred revenue | 0 | (7,052) |
Other liabilities | (536) | (469) |
Net cash used in operating activities | (9,541) | (28,382) |
Cash flows from investing activities: | ||
Purchase of available-for-sale securities | (2,000) | (1,499) |
Proceeds from sale or maturity of available-for-sale securities | 0 | 5,998 |
Capital expenditures | 0 | (10) |
Proceeds from sale of property and equipment | 211 | 0 |
Net cash (used in) provided by investing activities | (1,789) | 4,489 |
Cash flows from financing activities: | ||
Repayment of long-term debt | 0 | (7,500) |
Payment of long-term debt fees and issuance costs | 0 | (506) |
Proceeds from common stock offering | 5,440 | 5,040 |
Payment of common stock financing costs | (843) | (154) |
Payment of exercise of common stock warrants | (800) | 0 |
Proceeds from issuance of employee stock purchase plan | 0 | 4 |
Proceeds from exercise of common stock warrants | 0 | 14 |
Proceeds from exercise of common stock options | 0 | 1 |
Payments for minimum statutory tax withholding related to net share settlement of equity awards | (122) | (4) |
Net cash provided by (used in) provided by financing activities | 3,675 | (3,105) |
Net decrease in cash, cash equivalents, and restricted cash | (7,655) | (26,998) |
Cash, cash equivalents, and restricted cash - beginning of period | 9,777 | 43,844 |
Cash, cash equivalents, and restricted cash - end of period | 2,122 | 16,846 |
Non-cash investing activities: | ||
Other receivable from sale of property and equipment | $ 711 | $ 0 |
UNAUDITED CONDENSED CONSOLIDA_7
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Statement of Cash Flows [Abstract] | ||
Cash and cash equivalents | $ 922 | $ 8,577 |
Restricted cash included in other noncurrent assets | 1,200 | 1,200 |
Total cash, cash equivalents, and restricted cash shown in the unaudited condensed consolidated statements of cash flows | $ 2,122 | $ 9,777 |
Description of Business, Basis
Description of Business, Basis of Presentation and Going Concern | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Description of Business, Basis of Presentation and Going Concern | Description of Business, Basis of Presentation and Going Concern Description of Business Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. While the foregoing efforts are continuing with respect to the Company’s historical assets, the Company does not expect they will generate significant value for stockholders. Therefore, the Company is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization. The Company is exploring transactions in industries unrelated to its historical operations. Throughout these unaudited condensed consolidated financial statements, the terms the “Company,” and “Exicure” refer to Exicure, Inc. and where appropriate, its wholly owned subsidiary, Exicure Operating Company. Exicure Operating Company holds all material assets and conducts all business activities and operations of Exicure, Inc. Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of September 30, 2023 and December 31, 2022, and for the three and nine months ended September 30, 2023 and 2022, have been presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation. Unaudited Interim Financial Information The accompanying interim condensed consolidated balance sheet as of September 30, 2023, the interim condensed consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022, the interim condensed consolidated statements of comprehensive loss for the three and nine months ended September 30, 2023 and 2022, the interim condensed consolidated statements of changes in stockholders’ equity for the three and nine months ended September 30, 2023 and 2022, and the interim condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited financial statements and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended; and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the Company’s financial position as of September 30, 2023, the results of its operations for the three and nine months ended September 30, 2023 and 2022, and the results of its cash flows for the nine months ended September 30, 2023 and 2022. The financial data and other information disclosed in these notes related to the nine months ended September 30, 2023 and 2022 are unaudited. The results for the nine months ended September 30, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023, or any other interim periods, or any future year or period. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 27, 2023. Going Concern At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern for a period of one year after the date that the financial statements are issued. As of September 30, 2023, the Company has generated an accumulated deficit of $206,913, including $18,837 of additional paid-in capital reclassed to accumulated deficit upon C-corporation conversion, since inception and expects to incur significant expenses and negative cash flows for the foreseeable future. As of September 30, 2023, the Company’s cash and cash equivalents were $922. Management believes that, given the Company’s current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. Substantial additional financing will be needed by the Company to fund its operations. Management believes that the Company’s existing cash and cash equivalents are insufficient to continue to fund its operating expenses and additional funding is needed in the very near term. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend the Company’s operating runway is limited. As a result, substantial additional financing will be needed by the Company in the very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms. The accompanying unaudited condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. |
Significant Accounting Policies
Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto, which are included in the in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 27, 2023, as amended by Amendment No. 1 filed with the SEC on May 1, 2023 (the “Annual Report”). Since the date of those audited consolidated financial statements, there have been no material changes to the Company’s significant accounting policies, except for the investment in convertible notes receivable. Use of Estimates The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates. Investment in Convertible Notes Receivable Securities are classified as current or noncurrent based on the remaining contractual maturities of the securities. Securities are designated by the Company at the point of investment, as either trading, AFS, or held to maturity. Under ASC 825, Financial Instruments, the Company elected the fair value option for all outstanding convertible notes receivable. Management evaluates the performance of the securities on a fair value basis. Under the fair value option, the notes receivable are measured at each reporting period based upon their exit value in an orderly transaction and unrealized gains or losses from changes in fair value are recorded in the Condensed Consolidated Statements of Operations. Investment in convertible notes receivable at fair value totaled $0 as of September 30, 2023. As of September 30, 2023, the aggregate cost of the investment in convertible notes receivable accounted for under the fair value option was $0, which included principal balances of $2,000 and the change in fair value of $2,000. Recent Accounting Pronouncements Adopted Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326) (“ASU 2016-13”). This ASU changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard replaces the “incurred loss” approach with an “expected loss” model. The new model, referred to as the current expected credit loss (“CECL”) model, will apply to: (1) financial assets subject to credit losses and measured at amortized cost, and (2) certain off-balance sheet credit exposures. ASU 2016-13 also expands the disclosure requirements regarding an entity’s assumptions, models, and methods for estimating the allowance for credit losses. ASU No. 2016-13 was effective for the Company beginning on January 1, 2020. The Company adopted this ASU in January 2023. There was no material impact on the condensed consolidated financial statements. |
Supplemental Balance Sheet Info
Supplemental Balance Sheet Information | 9 Months Ended |
Sep. 30, 2023 | |
Supplemental Balance Sheet Information [Abstract] | |
Supplemental Balance Sheet Information | Supplemental Balance Sheet Information Prepaid expenses and other current assets September 30, 2023 December 31, 2022 Prepaid clinical, contract research and manufacturing costs $ — $ 213 Prepaid insurance 554 408 Prepaid franchise tax 330 223 Lease costs 296 111 Other 277 519 Prepaid expenses and other current assets $ 1,457 $ 1,474 Other noncurrent assets September 30, 2023 December 31, 2022 Restricted cash $ 1,200 $ 1,200 Prepaid insurance 1,892 2,252 Other — 38 Other noncurrent assets $ 3,092 $ 3,490 Property and equipment, net September 30, 2023 December 31, 2022 Scientific equipment $ 246 $ 6,087 Computers and software 3 63 Furniture and fixtures 30 30 Property and equipment, gross 279 6,180 Less: accumulated depreciation and amortization (218) (3,650) Property and equipment, net $ 61 $ 2,530 Depreciation and amortization expense was $627 and $882 for the nine months ended September 30, 2023 and 2022, respectively. During the nine months ended September 30, 2023, the Company sold scientific equipment with a net book value of $1,834 and recognized a loss of $920 included in other income (expense) in the accompanying statement of operations for the nine months ended September 30, 2023. Accrued expenses and other current liabilities September 30, 2023 December 31, 2022 Accrued clinical, contract research and manufacturing costs $ — $ 48 Accrued restructuring costs — 48 Lease liability 603 539 Accrued payroll-related expenses 43 32 Accrued federal and state tax payable — 209 Accrued other expenses 710 402 Accrued expenses and other current liabilities $ 1,356 $ 1,278 |
Leases
Leases | 9 Months Ended |
Sep. 30, 2023 | |
Leases [Abstract] | |
Leases | Leases The Company’s lease arrangements at September 30, 2023 consist of (i) a lease for office and laboratory space at its headquarters in Chicago, Illinois that commenced in July 2020 (the “Chicago Lease”) and (ii) a lease for office equipment (the “Office Equipment Lease”). The Chicago Lease and the Office Equipment Lease are classified as operating leases. Chicago Lease The Company has approximately thirty thousand square feet of office and laboratory space in Chicago, Illinois. The original term (the “Original Term”) of the Chicago Lease is 10 years, commencing on July 1, 2020 (the “Commencement Date”), which is the date the premises were ready for occupancy under the terms of the Chicago Lease. The Company has options to extend the term of the Chicago Lease for two additional successive periods of five years each (the “Extension Periods”) at the then prevailing effective market rental rate. The initial annual base rent during the Original Term is approximately $1,113 for the first 12-month period of the Original Term, payable in monthly installments beginning on the Commencement Date. Base rent thereafter is subject to annual increases of 3%, for an aggregate amount of $12,761 over the Original Term. The Company must also pay its proportionate share of certain operating expenses and taxes for each calendar year during the term. During the first 12-month period of the Original Term, the base rent and the Company's proportionate share of operating expenses and taxes were subject to certain abatements. The following table summarizes lease costs in the Company’s unaudited condensed consolidated statement of operations: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Operating lease costs $ 52 $ 326 $ 704 $ 979 Variable lease costs 232 341 545 1,187 Short term lease costs — 2 — 17 Total lease costs $ 284 $ 669 $ 1,249 $ 2,183 The Company made cash payments for operating leases $1,379 and $2,364 during the nine months ended September 30, 2023 and 2022, respectively. Sublease of Office Space The Company entered into a sublease agreement with Cyclopure, Inc. (the “Subtenant”) to sublease approximately 57% of its office space pursuant to that certain sublease agreement (the “Sublease Agreement”), dated as of May 4, 2023. The term of the Sublease Agreement began on May 15, 2023 and ends on June 30, 2030, the expiration date of the Chicago Lease. The first three months under the Sublease Agreement are rent free. Beginning August 15, 2023, the Company began charging the Subtenant for 57% of the base rent under the Chicago Lease, and the subtenant is responsible for its pro rata share of operating expenses and taxes payable. The following table summarizes sublease receipts in the Company’s unaudited condensed consolidated statement of operations: Three Months Ended Nine Months Ended 2023 2023 Sublease receipts $ 179 $ 179 Total $ 179 179000 $ 179 |
Investment in Convertible Notes
Investment in Convertible Notes Receivable | 9 Months Ended |
Sep. 30, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |
Investment in Convertible Notes Receivable | Investment in Convertible Notes Receivable In May 2023, the Company entered into two subscription agreements to purchase non-guaranteed private placement convertible bonds (the “Bonds”) for a subscription amount of $1 million each. The Bonds mature in May 2026 and the yield to maturity is 4.5% per annum. The Company has the option to request that the issuer redeem part or the entire principal amount of the Bonds on the first anniversary after the issue date and every three months thereafter before the maturity date. The conversion ratio will be one hundred percent (100%) of the Bond’s face value. The Company also has the ability to convert the debt into shares based on the number of shares computed by dividing the face value of each security by a calculated conversion price, which is subject to adjustment provisions, determined at the time of issuance. The securities may be converted from May 3, 2024, the first anniversary of the issue date of the first agreement, to April 15, 2026, one month prior to the maturity date to the second agreement. In March 2024, the Company notified the issuer of the Bonds that it was exercising its redemption right with respect to the entire principal amount of the Bonds after the first anniversary of their issue dates (May 3 and May 16, 2024, respectively) for an aggregate redemption price of $2.090 million (representing the principal amount plus 4.5% per annum yield to the redemption date). The Company’s debt securities are classified as AFS pursuant to ASC 320 - Investments - Debt Securities. AFS securities are recorded at fair value. As of September 30, 2023, management does not believe these AFS investments are recoverable and booked a change in fair value to record them at a fair value of $0. The Company held no AFS debt securities as of December 31, 2022. |
Stockholders' Equity
Stockholders' Equity | 9 Months Ended |
Sep. 30, 2023 | |
Equity [Abstract] | |
Stockholders' Equity | Stockholders’ Equity Preferred Stock As of September 30, 2023 and December 31, 2022, the Company had 10,000,000 shares of preferred stock, par value $0.0001 authorized and no shares issued and outstanding. Common Stock As of September 30, 2023 and December 31, 2022, the Company had authorized 200,000,000 shares of common stock, par value $0.0001. As of September 30, 2023 and December 31, 2022, the Company had 8,650,515 shares and 4,965,901 shares issued and outstanding, respectively. The holders of shares of the Company’s common stock are entitled to one vote per share on all matters to be voted upon by the Company’s stockholders and there are no cumulative rights. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of the Company’s common stock are entitled to receive ratably any dividends that may be declared from time to time by the Board of Directors (the “Board”) out of funds legally available for that purpose. In the event of the Company’s liquidation, dissolution or winding up, the holders of shares of the Company’s common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Company’s common stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Company’s common stock. The outstanding shares of the Company’s common stock are fully paid and non-assessable. September 2022 PIPE (Private Investment in Public Equity) Securities Purchase Agreement On September 26, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with CBI USA, Inc. (“CBI USA”), pursuant to which the Company agreed to issue and sell to CBI USA in a private placement an aggregate of 3,400,000 shares of Common Stock, at a purchase price of $1.60 per share. The private placement closed on February 24, 2023 (the “Closing Date”). The Company received gross proceeds of $5,440 from the September 2022 PIPE (or net proceeds of $4,597 after transaction expenses). CBI USA funded the acquisition pursuant to the Securities Purchase Agreement through a loan from its affiliate, DGP Co., Ltd. (“DGP”). On June 23, 2023, DGP exercised its the option pursuant to the loan and acquired the 3,400,000 shares of Common Stock initially acquired by CBI USA pursuant to the Securities Purchase Agreement. DGP subsequently agreed to sell its shares to a third party, with the closing of 10% (340,000 shares) occurring in February 2024 and the remainder to close by or on June 30, 2024. The Securities Purchase Agreement, as confirmed and clarified by that certain letter agreement, dated October 31, 2022, between the Company and CBI USA, provided CBI USA together with its affiliates and any “group” of which it or they are a member with the right to designate directors to the Company’s board of directors in proportion to the ownership of CBI USA and its affiliates and any such group. CBI USA and DGP have announced they expect to exercise such rights as a group. Together, they beneficially own 45% of the outstanding shares of Common Stock based on their most recent Schedule 13D amendment. As noted above, DGP has entered into an agreement to sell its remaining shares to a third party by or on June 30, 2024. September 2022 Registration Rights Agreement In connection with the Securities Purchase Agreement, the Company entered into a registration rights agreement with CBI USA (the “Registration Rights Agreement’). CBI USA assigned its rights under the Registration Rights Agreement to DGP when DGP acquired the 3,400,000 shares of Common Stock initially sold to CBI USA. Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the shares of Common Stock sold pursuant to the Securities Purchase Agreement, to use reasonable best efforts to cause such registration statement to become effective as promptly as practicable, and to keep such registration statement continuously effective until the earlier of (i) the date the shares covered by such registration statement have been sold or may be resold pursuant to Rule 144 without restriction, or (ii) the date that is two (2) years following the Closing Date. In the event the registration statement was not filed within 90 days following the Closing Date, subject to certain limited exceptions, the Company agreed to make payments as liquidated damages in an amount equal to 0.5% of the aggregate amount invested in the shares of Common Stock pursuant to the Securities Purchase Agreement per 30-day period or pro rata for any portion thereof for each such month during which such event continues, subject to certain caps set forth in the Registration Rights Agreement. We have paid $27 to CBI USA and accrued $82 to DGP pursuant to this provision. May 2022 PIPE Securities Purchase Agreement On May 9, 2022, the Company entered into a securities purchase agreement (the “May 2022 Securities Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 867,369 shares (the “May 2022 PIPE Shares”) of the Company’s Common Stock, par value $0.0001 per share, at a purchase price of $5.81 per share (the “May 2022 PIPE”). The May 2022 PIPE closed on May 18, 2022 (the “May 2022 PIPE Closing Date”). The Company received aggregate net proceeds from the May 2022 PIPE of approximately $4,886 after deducting transaction-related expenses. Registration Rights Agreement Also, on May 9, 2022, the Company entered into a registration rights agreement (the “May 2022 Registration Rights Agreement”) with the Investors, pursuant to which the Company agreed to register the resale of the May 2022 PIPE Shares. Under the May 2022 Registration Rights Agreement, the Company agreed to file a registration statement covering the resale of the Shares no later than July 18, 2022. On July 11, 2022, the Company filed a registration statement on Form S-3 with the SEC for the resale of the Shares and caused the registration statement to become effective on July 20, 2022. The Company has granted the Investors customary indemnification rights in connection with the registration statement. The Investors have also granted the Company customary indemnification rights in connection with the registration statement. Registered Direct Offering On December 16, 2021, the Company completed a securities purchase agreement (the “Purchase Agreement”) with certain institutional purchasers (the “Purchasers”) entered into on December 14, 2021, pursuant to which the Company offered to the Purchasers, in a registered direct offering priced at-the-market consistent with the rules of Nasdaq (the “Registered Direct Offering”), (i) an aggregate of 433,553 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share, (ii) pre-funded warrants to purchase up to an aggregate of 718,981 shares of Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase up to 576,261 shares of Common Stock (the “Warrants”). The combined purchase price of each share of Common Stock and accompanying Warrant is $9.9780 per share. The combined purchase price of each Pre-Funded Warrant and accompanying Warrant is $9.9480 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.03). The per share exercise price for the Warrants is $8.1031, the closing bid price of the Company’s Common Stock on December 13, 2021 (and as adjusted for the reverse stock split referenced in Note 1). The Warrants will be exercisable immediately from the closing December 16, 2021, and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants and Warrants, which met equity classification, were recognized as a component of permanent stockholders’ equity within additional paid-in-capital together with the net proceeds from the Registered Direct Offering. The gross proceeds to the Company from the Registered Direct Offering (excluding effect of subsequent exercises of pre-funded warrants) were $11,478 and net proceeds after deducting the placement agent’s fees and other offering expenses paid or payable by the Company were $10,226. The securities were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-251555) previously filed with the Securities and Exchange Commission (the “SEC”) on December 21, 2020, and which was declared effective by the SEC on January 7, 2021 (the “Registration Statement”). Each Warrant is exercisable for one share of Common Stock at an exercise price of $8.1031 per share. The Warrants are immediately exercisable as of the date of issuance of December 16, 2021 and will expire on the five-year anniversary of the date of issuance, or December 16, 2026. The Pre-Funded Warrants were offered in lieu of shares of Common Stock to one of the Purchasers whose purchase of shares of Common Stock in the Registered Direct Offering would otherwise result in said Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Registered Direct Offering. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.030 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder (together with its affiliates) of the Warrant or Pre-Funded Warrant may not exercise any portion of the Warrant or Pre-Funded Warrant, as applicable, to the extent that the holder would own more than 4.99% (or, at the holder’s option upon issuance, 9.99%) of the Company’s outstanding Common Stock immediately after exercise, as such percentage ownership is determined in accordance with the terms of the Warrant or Pre-Funded Warrant, as applicable. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrants, provided that such cashless exercise shall only be permitted if the Registration Statement is not effective at the time of such exercise or if the prospectus to which the Registration Statement is a part is not available for the issuance of shares of Common Stock to the Warrant holder. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Pre-Funded Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants. Common Stock Warrants In January 2022, Pre-Funded Warrants were exercised for a total exercise price of $14, resulting in the issuance of 466,666 shares of common stock. As of September 30, 2023, there are no unexercised pre-funded warrants that are outstanding. Warrants to purchase 576,261 shares of common stock at a price of $8.1031 per share were acquired in the December 2021 registered-direct offering transaction. The warrants were classified as equity. As a result of the closing of the September 2022 PIPE, a warrant holder elected to exercise their option within 30 days of the closing of the September 2022 PIPE (February 24, 2023) to receive a cash payout for the outstanding warrants in the amount of the Black-Scholes value of each warrant as prescribed in the warrant agreement. The Company paid $800 to this warrant holder on June 23, 2023 and 526,151 were settled as a result. As of September 30, 2023, warrants to purchase 50,110 shares of common stock at a price of $8.1031 per share that were acquired in the December 2021 registered-direct offering transaction remain outstanding. |
Equity-Based Compensation
Equity-Based Compensation | 9 Months Ended |
Sep. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Equity-Based Compensation | Equity-Based Compensation 2017 Equity Incentive Plan On September 22, 2017, the Company’s stockholders approved the Exicure, Inc. 2017 Equity Incentive Plan (the “2017 Plan”), which became effective on November 15, 2017. The 2017 Plan provides for the issuance of incentive awards of up to 194,750 shares of Exicure common stock, which includes 72,330 shares of Exicure common stock to be issued to officers, employees, consultants and directors, plus a number of shares not to exceed 122,793 that are subject to issued and outstanding awards under the Exicure OpCo 2015 Equity Incentive Plan (the “2015 Plan”) and were assumed in the merger transaction on September 26, 2017. Awards that may be awarded under the 2017 Equity Incentive Plan include non-qualified and incentive stock options, stock appreciation rights, bonus shares, restricted stock, restricted stock units, performance units and cash-based awards. The number of shares of common stock reserved for issuance under the 2017 Equity Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2020, by the lesser of (i) 153,333 shares, (ii) 5% of the total number of shares of its capital stock outstanding on December 31 of the preceding calendar year, or (iii) a lesser number of shares determined by the Compensation Committee of the Board (the “Compensation Committee”). No future awards will be made under the 2015 Plan upon the effectiveness of the 2017 Plan. On January 1, 2023, pursuant to the terms of the 2017 Plan, the number of awards that are reserved and may be awarded under the 2017 Plan was automatically increased by 153,333 awards. As of September 30, 2023, the aggregate number of equity awards available for grant under the 2017 Equity Incentive Plan was 454,360. Awards granted under the 2017 Plan are contingent on the participants’ continued employment or provision of non-employee services and are subject to forfeiture if employment or continued service terminates for any reason. The initial award granted to an employee or consultant generally vests 25% on the first 12-month anniversary of the grant date and vests 1/48th monthly thereafter until fully vested at the end of 48 months. Subsequent awards granted to employees or consultants generally vest 1/48th monthly until fully vested at the end of 48 months. The initial stock option grant to a non-employee director vests 1/36th monthly until fully vested at the end of 36 months. Subsequent stock option grants to a non-employee director vests 1/12th monthly until fully vested at the end of 12 months. The term of common stock option grants is 10 years unless terminated earlier as described above. Employee Stock Purchase Plan The 2017 Employee Stock Purchase Plan (the “ESPP”) was adopted by the Board in September 2017 and approved by the Company’s stockholders in September 2017. Through the ESPP, eligible employees may authorize payroll deductions of up to 15% of their compensation to purchase common stock. The maximum number of shares that an employee may purchase on any exercise date in an offer period will be the smaller of (i) 250 shares or (ii) such number of shares as has a fair market value (determined as of the offering date for such offer period) equal to $25,000 within one calendar year minus the fair market value of any other shares of common stock that are attributed to such calendar year. The purchase price per share at each purchase date is equal to 85% of the lower of (i) the closing market price per share of Exicure common stock on the employee’s offering date or (ii) the closing market price per share of Exicure common stock on the exercise date. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2018 and each January 1 thereafter through January 1, 2027, by the least of (i) 10,000 shares; (ii) 0.3% of the outstanding shares of common stock on the last day of the immediately preceding calendar year; or (iii) a lesser number of shares determined by the Board. On January 1, 2023, the number of shares of common stock available for issuance under the ESPP increased by 10,000 shares. As of September 30, 2023, there were 51,971 shares available for issuance under the ESPP. Equity-based compensation expense is classified in the statements of operations as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Research and development expense $ — $ 118 $ 154 $ 448 General and administrative expense 50 174 1,173 693 $ 50 $ 292 $ 1,327 $ 1,141 Unamortized equity-based compensation expense at September 30, 2023 was $586, which is expected to be amortized over a weighted-average period of 1.9 years. The Company utilizes the Black-Scholes option-pricing model to determine the fair value of common stock option grants. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. The model also requires the input of highly subjective assumptions. The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the nine months ended September 30, 2023 and 2022: Nine Months Ended Nine Months Ended 2023 2022 Expected term 5.8 to 5.8 years 5.3 to 6.1 years Risk-free interest rate 3.83% to 3.83%; weighted avg. 3.83% 2.86% to 3.56%; weighted avg. 2.90% Expected volatility 100.9% to 100.9%; weighted avg. 100.9% 95.2% to 95.8%; weighted avg. 95.2% Forfeiture rate 5 % 5 % Expected dividend yield — % — % The expected term is based upon the “simplified method” as described in Staff Accounting Bulletin Topic 14.D.2. Currently, the Company does not have sufficient experience to provide a reasonable estimate of an expected term of its common stock options. The Company will continue to use the “simplified method” until there is sufficient experience to provide a more reasonable estimate in conformance with ASC 718-10-30-25 through 30-26. The risk-free interest rate assumptions were based on the U.S. Treasury bond rate appropriate for the expected term in effect at the time of grant. For stock options granted after December 31, 2021, the expected volatility is based on the volatility of shares of the Company. For stock options granted prior to January 1, 2022, the expected volatility is based on calculated enterprise value volatilities for publicly traded companies in the same industry and general stage of development. The estimated forfeiture rates were based on historical experience for similar classes of employees. The dividend yield was based on expected dividends at the time of grant. The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2023 and 2022 are summarized in the table below. Common Stock Options Granted During Period Ended: Fair Value of Underlying Common Stock Exercise Price of Common Stock Option Nine months ended September 30, 2023 $1.58; weighted avg. $1.58 $1.58; weighted avg. $1.58 Nine months ended September 30, 2022 $3.46 to $5.51; weighted avg. $4.56 $3.46 to $5.51; weighted avg. $4.56 The weighted-average grant date fair value of common stock options granted in the nine months ended September 30, 2023 was $1.26 per common stock option. A summary of common stock option activity as of the periods indicated is as follows: Options Weighted-Average Exercise Price (1) Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value (thousands) Outstanding - December 31, 2022 222,833 $ 4.74 7.5 $ — Granted 10,000 1.58 Exercised — — Forfeited (220,718) 5.40 Outstanding - September 30, 2023 12,115 $ 4.28 5.7 $ — Exercisable - September 30, 2023 11,891 $ 4.26 5.6 $ — Vested and Expected to Vest - 12,115 $ 4.28 5.7 $ — (1) On March 24, 2022, the Company’s Board of Directors unanimously approved the repricing of all outstanding and unexercised stock options granted under our 2015 Equity Incentive Plan and 2017 Equity Incentive Plan and held by its current employees, executive officers, and directors. Effective April 1, 2022, the exercise price of the eligible stock options was reduced to $5.51, the closing price of our common stock on April 1, 2022. See below section titled “Repricing of Outstanding and Unexercised Options” for more information. A summary of restricted stock unit activity of the periods indicated is as follows: Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested balance - December 31, 2022 20,885 $ 12.65 Granted 295,992 1.02 Settled (308,689) 1.91 Forfeited (4,808) 14.58 Unvested balance - September 30, 2023 3,380 $ 10.41 The grant date fair value of restricted stock units is based on the Company’s closing stock price at the date of grant. At vesting, each outstanding restricted stock unit will be exchanged for one share of the Company’s common stock. Restricted stock units generally vest evenly on a quarterly basis over a period of 4 years in exchange for continued service provided by the restricted stock unit recipient during that vesting period. A summary of performance-based restricted stock unit activity of the periods indicated is as follows: Performance-Based Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested balance - December 31, 2022 97,643 $ 3.45 Granted — — Settled (97,643) 1.91 Unvested balance - September 30, 2023 — $ — |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income TaxesThe Company incurred a pretax loss in each of the nine months ended September 30, 2023 and 2022, which consists entirely of loss in the United States and resulted in no provision for income tax expense during the periods then ended. The effective tax rate is 0% in each of the nine months ended September 30, 2023 and 2022 because the Company has generated tax losses and has provided a full valuation allowance against its deferred tax assets. |
Loss Per Common Share
Loss Per Common Share | 9 Months Ended |
Sep. 30, 2023 | |
Earnings Per Share [Abstract] | |
Loss Per Common Share | Loss Per Common Share Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the nine months ended September 30, 2023 and 2022. The following is the computation of loss per common share for the nine months ended September 30, 2023 and 2022: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Net loss $ (5,256) $ (5,160) $ (15,427) $ (20,978) Weighted-average basic and diluted common shares outstanding 8,650,402 4,963,344 7,799,233 4,502,962 Loss per share - basic and diluted $ (0.61) $ (1.04) $ (1.98) $ (4.66) The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company’s loss per share during that period: As of September 30, 2023 2022 Options to purchase common stock 12,115 312,494 Restricted stock units 3,380 51,820 Performance stock units — 97,643 Warrants to purchase common stock 50,110 576,261 |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Sep. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements ASC Topic 820, Fair Value Measurement , establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, as follows: Level 1 Inputs - unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date; Level 2 Inputs - other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3 Inputs - unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. Assets measured at fair value on a recurring basis as of September 30, 2023 are as follows: Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 659 $ 659 $ — $ — Short-term investments: Investment in convertible notes receivable — — — — Total financial assets $ 659 $ 659 $ — $ — Assets measured at fair value on a recurring basis as of December 31, 2022 are as follows: Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 1,612 $ 1,612 $ — $ — Total financial assets $ 1,612 $ 1,612 $ — $ — The Company uses the market approach and Level 1 and Level 2 inputs to value its cash equivalents and Level 2 inputs to value its short-term investments. The Company uses the market approach and Level 3 inputs to value its liabilities. There were no liabilities measured at fair value on a recurring basis as of December 31, 2022. Warrant Liability A summary of the warrant liability activity for the nine months ended September 30, 2023 is as follows: Warrants Outstanding Fair Value Per Share Fair Value (in thousands, except per share data) Balance at December 31, 2022 — $ — $ — Option to exercise 526 $ 1.52 $ 800 Payment to warrant holder (526) $ 1.52 $ (800) Balance at September 30, 2023 — $ — — Investment in convertible notes receivable A summary of the AFS activity for the nine months ended September 30, 2023 is as follows: Fair Value Balance at December 31, 2022 $ — Investment in available for sale securities 2,000 Change in fair value of investment in convertible notes receivable (2,000) Balance at September 30, 2023 $ — As of September 30, 2023, management does not believe these AFS investments are recoverable and booked a change in fair value of $2,000. There were no transfers between Level 1, 2, or 3, during the years ended December 31, 2023, and 2022. Both observable and unobservable in puts were used to determine fair value of the positions that the Company classified within the Level 3 category. Unrealized gains and losses associated within the Level 3 category include changes in fair value that were attributable to both observable and unobservable inputs. |
Commitment and Contingencies
Commitment and Contingencies | 9 Months Ended |
Sep. 30, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Legal Proceedings On December 13, 2021, Mark Colwell filed a putative securities class action lawsuit against the Company, David A. Giljohann and Brian C. Bock in the United States District Court for the Northern District of Illinois, captioned Colwell v. Exicure, Inc. et al., Case No. 1:21-cv-0663. On February 4, 2021, plaintiff filed an amended putative securities class action complaint. On March 20, 2023, the court entered an order appointing James Mathew as lead plaintiff and Bleichmar Fonti & Auld LLP as lead counsel in the action pursuant to the Private Securities Litigation Reform Act of 1995. On May 26, 2023, lead plaintiff filed a second amended complaint against the Company, Dr. Giljohann, Mr. Bock, and Grant Corbett. The second amended complaint alleges that Dr. Giljohann, Mr. Bock, and Dr. Corbett made materially false and/or misleading statements related to the Company’s clinical programs purportedly causing losses to investors who acquired Company securities between January 7, 2021 and December 10, 2021. The second amended complaint does not quantify any alleged damages but, in addition to attorneys’ fees and costs, lead plaintiff seeks to recover damages on behalf of himself and others who acquired the Company’s stock during the putative class period at allegedly inflated prices and purportedly suffered financial harm as a result. The Case is currently stayed until May 22, 2024 to permit the parties to complete the voluntary private mediation. On March 1, 2022, Kapil Puri filed a shareholder derivative lawsuit on behalf of the Company in the United States District Court for the Northern District of Illinois, against Dr. Giljohann and Mr. Bock, Jeffrey L. Cleland, Elizabeth Garofalo, Bosun Hau, Bali Muralidhar, Andrew Sassine, Matthias Schroff, James Sulat and Timothy Walbert, captioned Puri v. Giljohann, et al., Case No. 1:22-cv-01083. On March 8, 2022, Yixin Sim filed a similar shareholder derivative lawsuit in the same court against the same individuals, captioned Sim v. Giljohann, et al., Case No. 1:22-cv-01217. On April 25, 2022, Stourbridge Investments LLC filed a similar shareholder derivative lawsuit against the same individuals in the United States District Court for the District of Delaware, captioned Stourbridge Investments LLC v. Exicure, Inc. et al., Case No. 1:22-cv-00526. Based on similar factual allegations presented in the Colwell complaint, described above, the Puri, Sim, and Stourbridge complaints (collectively, the “Derivative Complaints”) allege that the defendants caused the Company to issue false and/or misleading statements in the proxy statement for its 2021 Annual Meeting of Stockholders regarding risk oversight, code of conduct, clinical program and compensation matters, among other things, in violation of federal securities law, and committed breaches of fiduciary duties. The Derivative Complaints also assert that Dr. Giljohann and Mr. Bock are liable for contribution under the federal securities laws. The Puri and Stourbridge complaints further assert state law claims for unjust enrichment, and the Puri complaint additionally asserts state law claims for abuse of control, gross mismanagement and corporate waste. The plaintiffs do not quantify any alleged damages in the Derivative Complaints, but seek restitution for damages to the Company, attorneys’ fees, costs, and expenses, as well as an order directing that certain proposals for strengthening board oversight be put to a vote of the Company’s shareholders. On March 18, 2022, James McNabb, through counsel, sent a written demand to the Company (the “Demand Letter”) demanding that the Board of Directors investigate certain allegations and commence proceedings on the Company’s behalf against certain of the Company’s officers and directors for alleged breaches of fiduciary duties and corporate waste. All of the Derivative Cases have been stayed pending a decision on any motion to dismiss that may be filed in the Colwell case. In addition, the Stourbridge case has been administratively closed pending the decision on motion to dismiss that may be filed in the Colwell case. Further, pursuant to agreement, the Demand Letter is being held in abeyance and any related statute of limitations tolled pending such motion and decision. On October 3, 2023, a former employee filed a complaint against the Company and its executives related to the former employee’s separation from the Company. Northwestern University License Agreements On December 12, 2011, (1) AuraSense, LLC, the Company’s former parent, assigned to the Company all of its worldwide rights and interests under AuraSense, LLC’s 2009 license agreement with Northwestern University (“NU”) in the field of the use of nanoparticles, nanotechnology, microtechnology or nanomaterial-based constructs as therapeutics or accompanying therapeutics as a means of delivery, but expressly excluding diagnostics (the “assigned field”); (2) in accordance with the terms and conditions of this assignment, the Company assumed all liabilities and obligations of AuraSense, LLC as set forth in its license agreement in the assigned field; and (3) in order to secure this assignment and the patent rights from NU, the Company agreed (i) to pay NU an annual license fee, which may be credited against any royalties due to NU in the same year, (ii) to reimburse NU for expenses associated with the prosecution and maintenance of the license patent rights, (iii) to pay NU royalties based on any net revenue generated by the Company’s sale or transfer of any licensed product, (iv) to pay NU, in the event the Company grants a sublicense under the licensed patent rights, the greater of a percentage of all sublicensee royalties or a percentage of any net revenue generated by a sublicensee’s sale or transfer of any licensed product, and (v) to pay NU a percentage of all other sublicense payments received by the Company. In August 2015, the Company entered into a restated license agreement with NU (the “Restated License Agreement”). In February 2016, the Company obtained exclusive license as to NU’s rights in certain SNA technology it jointly owns with NU (the “Co-owned Technology License”). The Company’s license to NU’s rights is limited to the assigned field, however the Company has no such limitation as to its own rights in this jointly owned technology. The Company’s rights and obligations in the Co-owned Technology License agreement is substantially the same as in the Restated License Agreement from August 2015 (collectively referred to as “the Northwestern University License Agreements”). As of September 30, 2023, the Company has paid to NU an aggregate of $11,567 in consideration of each of the obligations described above. On August 3, 2023, the company received a notice letter (the “Letter”) from counsel for NU alleging the Company breached the Northwestern University License Agreements. The Letter alleges that a lack of development required under the Northwestern University License Agreements is a breach. The Northwestern University License Agreements were subsequently terminated on September 10, 2023 and October 3, 2023, respectively. Leases Refer to Note 4, Leases , for a discussion of the commitments associated with the Company’s lease agreements. |
Related-Party Transactions
Related-Party Transactions | 9 Months Ended |
Sep. 30, 2023 | |
Related Party Transactions [Abstract] | |
Related-Party Transactions | Related-Party Transactions Pursuant to a Consulting Agreement, effective as of September 25, 2022, between the Company and Alta Companies LTD (“Alta”), the Company paid Alta $218 on February 27, 2023 for a consulting fee earned as a result of the September 2022 PIPE closing. Paul Kang, a director of the Company since February 2023 and the CEO of the Company since August 2023, is the President of Alta. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events On May 3, 2024, the Company executed a promissory note (“Note”) and subsequently received a loan in the amount of $300 from an individual investor. All principal and accrued interest will be due and payable on the earlier of (i) the 1st anniversary of the date of this Note or (ii) upon an event of default, at that time, such amounts declared by the investor will become due and payable by Company. Interest will accrue on this Note at 6.0% and is payable at maturity. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation |
Principles of Consolidation | Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Exicure and its wholly owned subsidiary, Exicure Operating Company. All intercompany transactions and accounts are eliminated in consolidation. |
Use of Estimates | Use of Estimates |
Investments in Convertible Notes Receivable | Investment in Convertible Notes Receivable |
Recent Accounting Pronouncements Adopted | Recent Accounting Pronouncements Adopted Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326) (“ASU 2016-13”). This ASU changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The standard replaces the “incurred loss” approach with an “expected loss” model. The new model, referred to as the current expected credit loss (“CECL”) model, will apply to: (1) financial assets subject to credit losses and measured at amortized cost, and (2) certain off-balance sheet credit exposures. ASU 2016-13 also expands the disclosure requirements regarding an entity’s assumptions, models, and methods for estimating the allowance for credit losses. ASU No. 2016-13 was effective for the Company beginning on January 1, 2020. The Company adopted this ASU in January 2023. There was no material impact on the condensed consolidated financial statements. |
Loss Per Common Share | Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options, restricted stock units and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation for the periods presented because such shares had an anti-dilutive effect due to the net loss reported in those periods. |
Supplemental Balance Sheet In_2
Supplemental Balance Sheet Information (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Supplemental Balance Sheet Information [Abstract] | |
Schedule of Prepaid and Other Current Assets | Prepaid expenses and other current assets September 30, 2023 December 31, 2022 Prepaid clinical, contract research and manufacturing costs $ — $ 213 Prepaid insurance 554 408 Prepaid franchise tax 330 223 Lease costs 296 111 Other 277 519 Prepaid expenses and other current assets $ 1,457 $ 1,474 |
Schedule of Other Noncurrent Assets | Other noncurrent assets September 30, 2023 December 31, 2022 Restricted cash $ 1,200 $ 1,200 Prepaid insurance 1,892 2,252 Other — 38 Other noncurrent assets $ 3,092 $ 3,490 |
Schedule of Property and Equipment, Net | Property and equipment, net September 30, 2023 December 31, 2022 Scientific equipment $ 246 $ 6,087 Computers and software 3 63 Furniture and fixtures 30 30 Property and equipment, gross 279 6,180 Less: accumulated depreciation and amortization (218) (3,650) Property and equipment, net $ 61 $ 2,530 |
Schedule of Accrued expenses and other current liabilities | Accrued expenses and other current liabilities September 30, 2023 December 31, 2022 Accrued clinical, contract research and manufacturing costs $ — $ 48 Accrued restructuring costs — 48 Lease liability 603 539 Accrued payroll-related expenses 43 32 Accrued federal and state tax payable — 209 Accrued other expenses 710 402 Accrued expenses and other current liabilities $ 1,356 $ 1,278 |
Leases (Tables)
Leases (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Leases [Abstract] | |
Schedule of Lease Costs | The following table summarizes lease costs in the Company’s unaudited condensed consolidated statement of operations: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Operating lease costs $ 52 $ 326 $ 704 $ 979 Variable lease costs 232 341 545 1,187 Short term lease costs — 2 — 17 Total lease costs $ 284 $ 669 $ 1,249 $ 2,183 The following table summarizes sublease receipts in the Company’s unaudited condensed consolidated statement of operations: Three Months Ended Nine Months Ended 2023 2023 Sublease receipts $ 179 $ 179 Total $ 179 179000 $ 179 |
Equity-Based Compensation (Tabl
Equity-Based Compensation (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Equity-Based Compensation Expense Classification in Statement of Operations | Equity-based compensation expense is classified in the statements of operations as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Research and development expense $ — $ 118 $ 154 $ 448 General and administrative expense 50 174 1,173 693 $ 50 $ 292 $ 1,327 $ 1,141 |
Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants | The following table presents the assumptions used in the Black-Scholes option-pricing model for stock options granted during the nine months ended September 30, 2023 and 2022: Nine Months Ended Nine Months Ended 2023 2022 Expected term 5.8 to 5.8 years 5.3 to 6.1 years Risk-free interest rate 3.83% to 3.83%; weighted avg. 3.83% 2.86% to 3.56%; weighted avg. 2.90% Expected volatility 100.9% to 100.9%; weighted avg. 100.9% 95.2% to 95.8%; weighted avg. 95.2% Forfeiture rate 5 % 5 % Expected dividend yield — % — % The fair value of the underlying common stock and the exercise price for the common stock options granted during the nine months ended September 30, 2023 and 2022 are summarized in the table below. Common Stock Options Granted During Period Ended: Fair Value of Underlying Common Stock Exercise Price of Common Stock Option Nine months ended September 30, 2023 $1.58; weighted avg. $1.58 $1.58; weighted avg. $1.58 Nine months ended September 30, 2022 $3.46 to $5.51; weighted avg. $4.56 $3.46 to $5.51; weighted avg. $4.56 |
Schedule of Common Stock Option Activity | A summary of common stock option activity as of the periods indicated is as follows: Options Weighted-Average Exercise Price (1) Weighted-Average Remaining Contractual Term (years) Aggregate Intrinsic Value (thousands) Outstanding - December 31, 2022 222,833 $ 4.74 7.5 $ — Granted 10,000 1.58 Exercised — — Forfeited (220,718) 5.40 Outstanding - September 30, 2023 12,115 $ 4.28 5.7 $ — Exercisable - September 30, 2023 11,891 $ 4.26 5.6 $ — Vested and Expected to Vest - 12,115 $ 4.28 5.7 $ — (1) On March 24, 2022, the Company’s Board of Directors unanimously approved the repricing of all outstanding and unexercised stock options granted under our 2015 Equity Incentive Plan and 2017 Equity Incentive Plan and held by its current employees, executive officers, and directors. Effective April 1, 2022, the exercise price of the eligible stock options was reduced to $5.51, the closing price of our common stock on April 1, 2022. See below section titled “Repricing of Outstanding and Unexercised Options” for more information. |
Schedule of Restricted Stock Unit Awards Activity | A summary of restricted stock unit activity of the periods indicated is as follows: Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested balance - December 31, 2022 20,885 $ 12.65 Granted 295,992 1.02 Settled (308,689) 1.91 Forfeited (4,808) 14.58 Unvested balance - September 30, 2023 3,380 $ 10.41 |
Schedule of Performance-based Restricted Stock Unit Activity | A summary of performance-based restricted stock unit activity of the periods indicated is as follows: Performance-Based Restricted Stock Units Weighted-Average Grant Date Fair Value Unvested balance - December 31, 2022 97,643 $ 3.45 Granted — — Settled (97,643) 1.91 Unvested balance - September 30, 2023 — $ — |
Loss Per Common Share (Tables)
Loss Per Common Share (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Computation of loss per common share | The following is the computation of loss per common share for the nine months ended September 30, 2023 and 2022: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Net loss $ (5,256) $ (5,160) $ (15,427) $ (20,978) Weighted-average basic and diluted common shares outstanding 8,650,402 4,963,344 7,799,233 4,502,962 Loss per share - basic and diluted $ (0.61) $ (1.04) $ (1.98) $ (4.66) |
Schedule of Antidilutive Securities | The outstanding securities presented below were excluded from the calculation of loss per common share, for the periods presented, because such securities would have been anti-dilutive due to the Company’s loss per share during that period: As of September 30, 2023 2022 Options to purchase common stock 12,115 312,494 Restricted stock units 3,380 51,820 Performance stock units — 97,643 Warrants to purchase common stock 50,110 576,261 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | Assets measured at fair value on a recurring basis as of September 30, 2023 are as follows: Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 659 $ 659 $ — $ — Short-term investments: Investment in convertible notes receivable — — — — Total financial assets $ 659 $ 659 $ — $ — Assets measured at fair value on a recurring basis as of December 31, 2022 are as follows: Total Level 1 Level 2 Level 3 Assets Cash equivalents: Money market funds $ 1,612 $ 1,612 $ — $ — Total financial assets $ 1,612 $ 1,612 $ — $ — |
Schedule of Warrant Liability Activity | A summary of the warrant liability activity for the nine months ended September 30, 2023 is as follows: Warrants Outstanding Fair Value Per Share Fair Value (in thousands, except per share data) Balance at December 31, 2022 — $ — $ — Option to exercise 526 $ 1.52 $ 800 Payment to warrant holder (526) $ 1.52 $ (800) Balance at September 30, 2023 — $ — — |
Schedule of Available-For-Sale Securities | A summary of the AFS activity for the nine months ended September 30, 2023 is as follows: Fair Value Balance at December 31, 2022 $ — Investment in available for sale securities 2,000 Change in fair value of investment in convertible notes receivable (2,000) Balance at September 30, 2023 $ — |
Description of Business, Basi_2
Description of Business, Basis of Presentation and Going Concern (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Accounting Policies [Abstract] | ||
Accumulated deficit generated, since inception | $ 206,913 | |
Additional paid-in capital, since inception | 18,837 | |
Cash and cash equivalents | $ 922 | $ 8,577 |
Significant Accounting Polici_3
Significant Accounting Policies (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Accounting Policies [Abstract] | |||||
Available-for-sale securities | $ 0 | $ 0 | $ 0 | ||
Aggregate cost | 0 | 0 | |||
Principal amount | 2,000,000 | 2,000,000 | |||
Changes in fair value of investment in convertible notes receivable | $ 2,000,000 | $ 0 | $ 2,000,000 | $ 0 |
Supplemental Balance Sheet In_3
Supplemental Balance Sheet Information - Schedule of Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Supplemental Balance Sheet Information [Abstract] | ||
Prepaid clinical, contract research and manufacturing costs | $ 0 | $ 213 |
Prepaid insurance | 554 | 408 |
Prepaid franchise tax | 330 | 223 |
Lease costs | 296 | 111 |
Other | 277 | 519 |
Prepaid expenses and other current assets | $ 1,457 | $ 1,474 |
Supplemental Balance Sheet In_4
Supplemental Balance Sheet Information - Schedule of Other Noncurrent Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Supplemental Balance Sheet Information [Abstract] | ||
Restricted cash | $ 1,200 | $ 1,200 |
Prepaid insurance | 1,892 | 2,252 |
Other | 0 | 38 |
Other noncurrent assets | $ 3,092 | $ 3,490 |
Supplemental Balance Sheet In_5
Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 279 | $ 6,180 |
Less: accumulated depreciation and amortization | (218) | (3,650) |
Property and equipment, net | 61 | 2,530 |
Scientific equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 246 | 6,087 |
Computers and software | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | 3 | 63 |
Furniture and fixtures | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment, gross | $ 30 | $ 30 |
Supplemental Balance Sheet In_6
Supplemental Balance Sheet Information - Narrative (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Property, Plant and Equipment [Line Items] | ||
Depreciation and amortization | $ 627 | $ 882 |
Loss from sale of property and equipment | 920 | $ 23 |
Scientific equipment | ||
Property, Plant and Equipment [Line Items] | ||
Sale of scientific equipment | 1,834 | |
Loss from sale of property and equipment | $ 920 |
Supplemental Balance Sheet In_7
Supplemental Balance Sheet Information - Schedule of Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Supplemental Balance Sheet Information [Abstract] | ||
Accrued clinical, contract research and manufacturing costs | $ 0 | $ 48 |
Accrued restructuring costs | 0 | 48 |
Lease liability | 603 | 539 |
Accrued payroll-related expenses | 43 | 32 |
Accrued federal and state tax payable | 0 | 209 |
Accrued other expenses | 710 | 402 |
Accrued expenses and other current liabilities | $ 1,356 | $ 1,278 |
Leases - Narrative (Details)
Leases - Narrative (Details) ft² in Thousands, $ in Thousands | 9 Months Ended | |||
May 04, 2023 | Jul. 01, 2020 USD ($) ft² extension_period | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | |
Lessee, Lease, Description [Line Items] | ||||
Operating lease, cash payments | $ 1,379 | $ 2,364 | ||
Chicago | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease area | ft² | 30 | |||
Operating lease, contract term | 10 years | |||
Operating lease, number of extensions | extension_period | 2 | |||
Operating lease, renewal term | 5 years | |||
Operating lease, annual rent payment | $ 1,113 | |||
Operating lease, base rent annual percentage increase (as a percent) | 3% | |||
Operating lease, estimated rental payment over lease term | $ 12,761 | |||
Sublease percentage of office space subtenant (as a percent) | 57% | |||
Period of no rental cost | 3 months |
Leases - Lease Costs (Details)
Leases - Lease Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Leases [Abstract] | ||||
Operating lease costs | $ 52 | $ 326 | $ 704 | $ 979 |
Variable lease costs | 232 | 341 | 545 | 1,187 |
Short term lease costs | 0 | 2 | 0 | 17 |
Total lease costs | $ 284 | $ 669 | $ 1,249 | $ 2,183 |
Leases - Sublease Receipts (Det
Leases - Sublease Receipts (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2023 | Sep. 30, 2023 | |
Leases [Abstract] | ||
Sublease receipts | $ 179 | $ 179 |
Investment in Convertible Not_2
Investment in Convertible Notes Receivable - Narrative (Details) | 1 Months Ended | 9 Months Ended | |||
Mar. 31, 2024 USD ($) | May 31, 2023 USD ($) agreement | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | |
Debt Securities, Available-for-sale [Line Items] | |||||
Available-for-sale securities | $ 0 | $ 0 | |||
Proceeds from sale or maturity of available-for-sale securities | $ 0 | $ 5,998,000 | |||
Convertible Bonds | |||||
Debt Securities, Available-for-sale [Line Items] | |||||
Number of subscription agreements entered into | agreement | 2 | ||||
Stated yield | 4.50% | ||||
Period in between reoccurring put option | 3 months | ||||
Face value conversion percentage | 100% | ||||
Convertible Bonds | Subsequent Event | |||||
Debt Securities, Available-for-sale [Line Items] | |||||
Stated yield | 4.50% | ||||
Proceeds from sale or maturity of available-for-sale securities | $ 2,090,000 | ||||
Convertible Bonds, One | |||||
Debt Securities, Available-for-sale [Line Items] | |||||
Available-for-sale securities | $ 1,000,000 | ||||
Convertible Bonds, Two | |||||
Debt Securities, Available-for-sale [Line Items] | |||||
Available-for-sale securities | $ 1,000,000 |
Stockholders' Equity - Preferre
Stockholders' Equity - Preferred Stock (Details) | Sep. 30, 2023 vote $ / shares shares | Dec. 31, 2022 $ / shares shares |
Equity [Abstract] | ||
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 |
Common stock, shares issued (in shares) | 8,650,515 | 4,965,901 |
Common stock, shares outstanding (in shares) | 8,650,515 | 4,965,901 |
Common stock, voting rights for each share | vote | 1 |
Stockholders' Equity - Securiti
Stockholders' Equity - Securities Purchase Agreement (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 9 Months Ended | |||||||
Jun. 23, 2023 | Sep. 26, 2022 | May 09, 2022 | Dec. 16, 2021 | Feb. 29, 2024 | Feb. 28, 2023 | Sep. 30, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Subsidiary, Sale of Stock [Line Items] | |||||||||
Common stock, shares outstanding (in shares) | 8,650,515 | 4,965,901 | |||||||
Registration rights agreement, required filing term | 90 days | ||||||||
Registration rights agreement, liquidation damages payable as a percent of amount invested, if filed late (as a percent) | 0.50% | ||||||||
Registration rights agreement, liquidation damages payable if filed late, measurement term | 30 days | ||||||||
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |||||||
Exercise price (in dollars per share) | $ 8.1031 | $ 8.1031 | |||||||
Warrant liability, measurement input, term | 5 years | ||||||||
Gross proceeds | $ 11,478 | ||||||||
Net proceeds | $ 10,226 | ||||||||
Ownership percentage limitation (as a percent) | 4.99% | ||||||||
Ownership percentage limitation at election of purchaser (as a percent) | 9.99% | ||||||||
Common stock, shares issued (in shares) | 8,650,515 | 4,965,901 | |||||||
DGP Co. Ltd | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Pro rata accrual | $ 82 | ||||||||
CBI USA, Inc | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Pro rata payment | $ 27 | ||||||||
Pre-Funded Warrants | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Warrants issued in sale of stock (in shares) | 718,981 | ||||||||
Exercise price (in dollars per share) | $ 0.030 | ||||||||
Number of shares exercisable for each warrant (in shares) | 1 | ||||||||
Warrant | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Warrants issued in sale of stock (in shares) | 576,261 | ||||||||
Exercise price (in dollars per share) | $ 8.1031 | ||||||||
Number of shares exercisable for each warrant (in shares) | 1 | ||||||||
Common Stock And Accompanying Warrant | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Purchase price (in dollars per share) | $ 9.9780 | ||||||||
Pre-Funded Warrants And Accompanying Warrant | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Purchase price (in dollars per share) | $ 9.9480 | ||||||||
Common Stock | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Number of shares issued in transaction (in shares) | 433,553 | ||||||||
Common stock, par value (in dollars per share) | $ 0.0001 | ||||||||
Private Placement | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Number of shares issued in transaction (in shares) | 3,400,000 | 867,369 | |||||||
Sales price of shares issued in transaction (in dollars per share) | $ 1.60 | $ 5.81 | |||||||
Consideration received, gross | $ 5,440 | ||||||||
Consideration for stock transaction | $ 4,886 | $ 4,597 | |||||||
Common stock, par value (in dollars per share) | $ 0.0001 | ||||||||
Private Placement | CBI USA & DGP Co. Ltd | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Percentage of ownership after transaction (as a percent) | 45% | ||||||||
Third Party Sale of Company Stock | CBI USA, Inc | DGP Co. Ltd | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Number of shares issued in transaction (in shares) | 3,400,000 | ||||||||
Third Party Sale of Company Stock | DGP Co. Ltd | Third Party | Subsequent Event | |||||||||
Subsidiary, Sale of Stock [Line Items] | |||||||||
Number of shares issued in transaction (in shares) | 340,000 | ||||||||
Percentage of shares subsequently sold at closing | 10% |
Stockholders' Equity - Common S
Stockholders' Equity - Common Stock Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 9 Months Ended | ||||
Jun. 23, 2023 | Jan. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2021 | Dec. 16, 2021 | |
Class of Warrant or Right [Line Items] | ||||||
Proceeds from warrant exercises | $ 0 | $ 14 | ||||
Number of shares called by warrants (in shares) | 50,110 | 576,261 | ||||
Exercise price (in dollars per share) | $ 8.1031 | $ 8.1031 | ||||
Payment for warrant liability | $ 800 | |||||
Warrants settled (in shares) | 526,151 | |||||
Pre-Funded Warrants | ||||||
Class of Warrant or Right [Line Items] | ||||||
Proceeds from warrant exercises | $ 14 | |||||
Shares issued for exercise of warrants (in shares) | 466,666 | |||||
Exercise price (in dollars per share) | $ 0.030 |
Equity-Based Compensation - Nar
Equity-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 9 Months Ended | ||
Jan. 01, 2023 | Sep. 30, 2017 | Sep. 30, 2023 | Sep. 22, 2017 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Compensation cost not yet recognized | $ 586 | |||
Compensation expense recognition period | 1 year 10 months 24 days | |||
Weighted-average grant date fair value (in dollars per share) | $ 1.26 | |||
Employee Stock | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares available for grant (in shares) | 51,971 | |||
Maximum ESPP contribution rate as a percentage of compensation (as a percent) | 15% | |||
Maximum number of shares per employee in purchase period (in shares) | 250 | |||
Maximum contribution amount | $ 25 | |||
ESPP purchase price as a percentage of market price (as a percent) | 85% | |||
Number of additional shares allowable annually under the plan (in shares) | 10,000 | |||
Percentage of outstanding shares allowable as annual increase (as a percent) | 0.30% | |||
Increase in number of shares available for grant (in shares) | 10,000 | |||
Restricted stock units | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting period | 4 years | |||
Number of shares issued for each vested restricted stock unit (in shares) | 1 | |||
Exicure, Inc. 2017 Equity Incentive Plan | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares authorized (in shares) | 194,750 | |||
Number of shares available for grant (in shares) | 454,360 | 72,330 | ||
Number of additional shares authorized, potential maximum additional shares (in shares) | 153,333 | |||
Number of additional shares authorized, percentage of common stock outstanding (as a percent) | 5% | |||
Exicure, Inc. 2017 Equity Incentive Plan | Share-based Payment Arrangement, Option | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares available for grant (in shares) | 153,333 | |||
Expiration period | 10 years | |||
Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Monthly vesting percentage (as a percent) | 2.08% | |||
Vesting period | 48 months | |||
Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | Non-employee Director | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Monthly vesting percentage (as a percent) | 2.78% | |||
Vesting period | 36 months | |||
Exicure, Inc. 2017 Equity Incentive Plan | Initial Employee Stock Option | Period One | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Vesting percentage (as a percent) | 25% | |||
Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Employee Stock Option | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Monthly vesting percentage (as a percent) | 2.08% | |||
Vesting period | 48 months | |||
Exicure, Inc. 2017 Equity Incentive Plan | Subsequent Employee Stock Option | Non-employee Director | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Monthly vesting percentage (as a percent) | 8.33% | |||
Vesting period | 12 months | |||
Exicure OpCo 2015 Equity Incentive Plan | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares available for grant (in shares) | 122,793 |
Equity-Based Compensation - Sch
Equity-Based Compensation - Schedule of Equity-Based Compensation Expense Classification in Statement of Operations (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based compensation expense | $ 50 | $ 292 | $ 1,327 | $ 1,141 |
Research and development expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based compensation expense | 0 | 118 | 154 | 448 |
General and administrative expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Share-based compensation expense | $ 50 | $ 174 | $ 1,173 | $ 693 |
Equity-Based Compensation - S_2
Equity-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Common Stock Option Grants (Details) | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Risk-free interest rate, minimum | 3.83% | 2.86% |
Risk-free interest rate, maximum | 3.83% | 3.56% |
Expected volatility, minimum | 100.90% | 95.20% |
Expected volatility, maximum | 100.90% | 95.80% |
Expected volatility | 100.90% | 95.20% |
Forfeiture rate | 5% | 5% |
Expected dividend yield | 0% | 0% |
Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term | 5 years 9 months 18 days | 5 years 3 months 18 days |
Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected term | 5 years 9 months 18 days | 6 years 1 month 6 days |
Weighted Average | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Risk-free interest rate | 3.83% | 2.90% |
Equity-Based Compensation - S_3
Equity-Based Compensation - Schedule of Fair Value of Underlying Common Stock and Exercise Price of Stock Options (Details) - $ / shares | Sep. 30, 2023 | Sep. 30, 2022 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Fair value of underlying common stock (in dollars per share) | $ 1.58 | |
Exercise price of common stock option (in dollars per share) | 1.58 | |
Weighted Average | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Fair value of underlying common stock (in dollars per share) | 1.58 | $ 4.56 |
Exercise price of common stock option (in dollars per share) | $ 1.58 | 4.56 |
Minimum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Fair value of underlying common stock (in dollars per share) | 3.46 | |
Exercise price of common stock option (in dollars per share) | 3.46 | |
Maximum | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Fair value of underlying common stock (in dollars per share) | 5.51 | |
Exercise price of common stock option (in dollars per share) | $ 5.51 |
Equity-Based Compensation - S_4
Equity-Based Compensation - Schedule of Stock Options Rollforward (Details) - USD ($) $ / shares in Units, $ in Thousands | 9 Months Ended | 12 Months Ended | |
Sep. 30, 2023 | Dec. 31, 2022 | Apr. 01, 2022 | |
Options | |||
Shares outstanding, beginning period (in shares) | 222,833 | ||
Granted (in shares) | 10,000 | ||
Exercise (in shares) | 0 | ||
Forfeited (in shares) | (220,718) | ||
Shares outstanding, ending period (in shares) | 12,115 | 222,833 | |
Exercisable (in shares) | 11,891 | ||
Vested and expected to vest (in shares) | 12,115 | ||
Weighted-Average Exercise Price | |||
Outstanding beginning balance (in dollars per share) | $ 4.74 | ||
Granted (in dollars per share) | 1.58 | ||
Exercised (in dollars per share) | 0 | ||
Forfeited (in dollars per share) | 5.40 | ||
Outstanding ending balance (in dollars per share) | 4.28 | $ 4.74 | |
Exercisable, weighted-average exercise price (in dollars per share) | 4.26 | ||
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ 4.28 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] | |||
Weighted-Average Remaining Contractual Term (years) | 5 years 8 months 12 days | 7 years 6 months | |
Exercisable, weighted-average remaining contractual term | 5 years 7 months 6 days | ||
Vested and expected to vest, weighted average remaining contractual term | 5 years 8 months 12 days | ||
Aggregate Intrinsic Value (thousands) | $ 0 | $ 0 | |
Exercisable, aggregate intrinsic value | 0 | ||
Vested and expected to vest, aggregate intrinsic value | $ 0 | ||
Stock option, exercise price (in dollars per share) | $ 5.51 |
Equity-Based Compensation - S_5
Equity-Based Compensation - Schedule of Restricted Stock Unit Awards Activity (Details) - Restricted stock units | 9 Months Ended |
Sep. 30, 2023 $ / shares shares | |
Restricted Stock Units | |
Unvested balance - beginning of period (in shares) | shares | 20,885 |
Granted (in shares) | shares | 295,992 |
Settled (in shares) | shares | (308,689) |
Forfeited (in shares) | shares | (4,808) |
Unvested balance - end of period (in shares) | shares | 3,380 |
Weighted-Average Grant Date Fair Value | |
Unvested balance - beginning of period (in dollars per share) | $ / shares | $ 12.65 |
Granted (in dollars per share) | $ / shares | 1.02 |
Settled (in dollars per share) | $ / shares | 1.91 |
Forfeited (in dollars per share) | $ / shares | 14.58 |
Unvested balance - end of period (in dollars per share) | $ / shares | $ 10.41 |
Equity-Based Compensation - Per
Equity-Based Compensation - Performance-based Restricted Stock Unit Activity (Details) - Performance Based Restricted Stock | 9 Months Ended |
Sep. 30, 2023 $ / shares shares | |
Performance-Based Restricted Stock Units | |
Unvested balance - beginning of period (in shares) | shares | 97,643 |
Granted (in shares) | shares | 0 |
Settled (in shares) | shares | (97,643) |
Unvested balance - end of period (in shares) | shares | 0 |
Weighted-Average Grant Date Fair Value | |
Unvested balance - beginning of period (in dollars per share) | $ / shares | $ 3.45 |
Granted (in dollars per share) | $ / shares | 0 |
Settled (in dollars per share) | $ / shares | 1.91 |
Unvested balance - end of period (in dollars per share) | $ / shares | $ 0 |
Income Taxes - Narrative (Detai
Income Taxes - Narrative (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Income Tax Disclosure [Abstract] | ||||
Provision for income taxes | $ 0 | $ 0 | $ 0 | $ 0 |
Effective tax rate (as a percent) | 0% | 0% |
Loss Per Common Share - Schedul
Loss Per Common Share - Schedule of Computation of loss per common share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||||||
Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Earnings Per Share [Abstract] | ||||||||
Net loss | $ (5,256) | $ (5,764) | $ (4,407) | $ (5,160) | $ (7,470) | $ (8,348) | $ (15,427) | $ (20,978) |
Weighted-average basic common shares outstanding (in shares) | 8,650,402 | 4,963,344 | 7,799,233 | 4,502,962 | ||||
Weighted-average diluted common shares outstanding (in shares) | 8,650,402 | 4,963,344 | 7,799,233 | 4,502,962 | ||||
Loss per share - basic (in dollars per share) | $ (0.61) | $ (1.04) | $ (1.98) | $ (4.66) | ||||
Loss per share - diluted (in dollars per share) | $ (0.61) | $ (1.04) | $ (1.98) | $ (4.66) |
Loss Per Common Share - Sched_2
Loss Per Common Share - Schedule of Antidilutive Securities (Details) - shares | 9 Months Ended | |
Sep. 30, 2023 | Sep. 30, 2022 | |
Options to purchase common stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) | 12,115 | 312,494 |
Restricted stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) | 3,380 | 51,820 |
Performance stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) | 0 | 97,643 |
Warrants to purchase common stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding (in shares) | 50,110 | 576,261 |
Fair Value Measurements - Sched
Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) | Sep. 30, 2023 | Dec. 31, 2022 |
Assets | ||
Investment in convertible notes receivable | $ 0 | $ 0 |
Fair Value, Recurring | ||
Assets | ||
Total financial assets | 659,000 | 1,612,000 |
Fair Value, Recurring | Convertible Bonds | ||
Assets | ||
Investment in convertible notes receivable | 0 | |
Fair Value, Recurring | Level 1 | ||
Assets | ||
Total financial assets | 659,000 | 1,612,000 |
Fair Value, Recurring | Level 1 | Convertible Bonds | ||
Assets | ||
Investment in convertible notes receivable | 0 | |
Fair Value, Recurring | Level 2 | ||
Assets | ||
Total financial assets | 0 | 0 |
Fair Value, Recurring | Level 2 | Convertible Bonds | ||
Assets | ||
Investment in convertible notes receivable | 0 | |
Fair Value, Recurring | Level 3 | ||
Assets | ||
Total financial assets | 0 | 0 |
Fair Value, Recurring | Level 3 | Convertible Bonds | ||
Assets | ||
Investment in convertible notes receivable | 0 | |
Money market funds | Fair Value, Recurring | ||
Assets | ||
Cash equivalents: | 659,000 | 1,612,000 |
Money market funds | Fair Value, Recurring | Level 1 | ||
Assets | ||
Cash equivalents: | 659,000 | 1,612,000 |
Money market funds | Fair Value, Recurring | Level 2 | ||
Assets | ||
Cash equivalents: | 0 | 0 |
Money market funds | Fair Value, Recurring | Level 3 | ||
Assets | ||
Cash equivalents: | $ 0 | $ 0 |
Fair Value Measurements - Sch_2
Fair Value Measurements - Schedule of Warrant Liability Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 9 Months Ended |
Sep. 30, 2023 USD ($) $ / shares shares | |
Warrants Outstanding | |
Beginning balance (in shares) | shares | 0 |
Option to exercise (in shares) | shares | 526 |
Payment to warrant holder (in shares) | shares | (526) |
Ending balance (in shares) | shares | 0 |
Fair Value Per Share | |
Beginning balance (in dollars per share) | $ / shares | $ 0 |
Option to exercise (in dollars per share) | $ / shares | 1.52 |
Payment to warrant holder (in dollars per share) | $ / shares | 1.52 |
Ending balance (in dollars per share) | $ / shares | $ 0 |
Warrants And Rights Outstanding [Roll Forward] | |
Balance at December 31, 2022 | $ | $ 0 |
Option to exercise | $ | 800 |
Payment to warrant holder | $ | (800) |
Balance at September 30, 2023 | $ | $ 0 |
Fair Value Measurements - Avail
Fair Value Measurements - Available For Sale Securities (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Debt Securities, Available-for-Sale [Roll Forward] | ||||
Balance at December 31, 2022 | $ 0 | |||
Investment in available for sale securities | 2,000,000 | |||
Change in fair value of investment in convertible notes receivable | $ (2,000,000) | $ 0 | (2,000,000) | $ 0 |
Balance at September 30, 2023 | $ 0 | $ 0 |
Fair Value Measurements - Narra
Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Fair Value Disclosures [Abstract] | ||||
Changes in fair value of investment in convertible notes receivable | $ 2,000 | $ 0 | $ 2,000 | $ 0 |
Commitment and Contingencies -
Commitment and Contingencies - Narrative (Details) $ in Thousands | Sep. 30, 2023 USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
Aggregate consideration paid to NU for agreement obligations | $ 11,567 |
Related-Party Transactions - Na
Related-Party Transactions - Narrative (Details) $ in Thousands | Feb. 27, 2023 USD ($) |
Related Party | |
Related Party Transaction [Line Items] | |
Amount of transaction | $ 218 |
Subsequent Events (Details)
Subsequent Events (Details) - Subsequent Event - Promissory Note | May 03, 2024 USD ($) |
Subsequent Event [Line Items] | |
Debt instrument, face amount | $ 300,000 |
Interest rate | 6% |